Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $20.7 million.

  • Orchestra BioMed Holdings' Total Current Liabilities rose 2735.85% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year increase of 2735.85%. This contributed to the annual value of $16.2 million for FY2024, which is 4460.21% up from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Total Current Liabilities stood at $20.7 million, which was up 2735.85% from $17.1 million recorded in Q2 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Total Current Liabilities peaked at $21.5 million during Q3 2023, and registered a low of $306538.0 during Q1 2022.
  • Over the past 4 years, Orchestra BioMed Holdings' median Total Current Liabilities value was $14.5 million (recorded in 2024), while the average stood at $12.6 million.
  • Examining YoY changes over the last 5 years, Orchestra BioMed Holdings' Total Current Liabilities showed a top increase of 383328.07% in 2023 and a maximum decrease of 3963.16% in 2023.
  • Over the past 4 years, Orchestra BioMed Holdings' Total Current Liabilities (Quarter) stood at $18.6 million in 2022, then tumbled by 39.63% to $11.2 million in 2023, then skyrocketed by 44.6% to $16.2 million in 2024, then rose by 27.44% to $20.7 million in 2025.
  • Its last three reported values are $20.7 million in Q3 2025, $17.1 million for Q2 2025, and $15.5 million during Q1 2025.